Related Experiment Video
Updated: Apr 5, 2026
Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors
Published on: July 16, 2012
PD-1/PD-L1 signal pathway participates in HCV F protein-induced T cell dysfunction in chronic HCV infection
Wen Xiao1, Long Feng Jiang2, Xiao Zhao Deng3,4
1School of Life Science and Technology, China Pharmaceutical University, No. 24, Tongjiaxiang, Nanjing, 210009, Jiangsu, China.
Abstract:
Programmed cell death-1/programmed cell death-1 ligand 1 (PD-1/PD-L1) inhibitory signal pathway has been verified to be involved in the establishment of persistent viral infections. Blockade of PD-1/PD-L1 engagement to reinvigorate T cell activity is supposed to be a potential therapeutic scheme. Studies have verified the participation of PD-1/PD-L1 in hepatitis C virus (HCV) core protein-regulated immune response. To determine the roles of PD-1/PD-L1 signal pathway in HCV F protein-induced immunoreaction in chronic HCV infection, variations in T cells were examined. The results showed that PD-1 expression on CD8(+) and CD4(+) T cells was increased with HCV F stimulation in both chronic HCV patients and healthy controls, and could be reduced partly by PD-1/PD-L1 blocking. Additionally, by PD-1/PD-L1 blocking, HCV F-induced inhibition of T cell proliferation and promotion of cellular apoptosis were partly or even totally recovered. Furthermore, levels of both Th1 and Th2 cytokines were elevated in the presence of anti-PD-L1 antibody. All these results indicated that PD-1/PD-L1 signal pathway also participates in HCV F protein-induced immunoregulation. PD-1/PD-L1 blocking plays important roles in the restoration of effective functionality of the impaired T cells in chronic HCV patients.
Insights
Blocking the PD-1/PD-L1 pathway can restore T cell function in chronic Hepatitis C virus (HCV) infection. This approach helps overcome HCV F protein-induced immune suppression, offering a potential therapeutic strategy.
Area of Science:
- Immunology
- Virology
- Hepatology
Background:
- The PD-1/PD-L1 pathway is crucial in persistent viral infections.
- PD-1/PD-L1 signaling is implicated in immune responses regulated by Hepatitis C virus (HCV) core protein.
- Therapeutic blockade of PD-1/PD-L1 aims to restore T cell activity.
Purpose of the Study:
- To investigate the role of the PD-1/PD-L1 pathway in HCV F protein-induced immune responses.
- To examine T cell variations in chronic HCV infection under PD-1/PD-L1 modulation.
- To assess the therapeutic potential of PD-1/PD-L1 blockade in restoring T cell function.
Main Methods:
- Examined T cell variations in chronic HCV patients and healthy controls upon HCV F stimulation.
- Assessed PD-1 expression on CD8(+) and CD4(+) T cells.
- Utilized PD-1/PD-L1 blocking agents to evaluate effects on T cell proliferation, apoptosis, and cytokine levels.
Main Results:
- HCV F stimulation increased PD-1 expression on T cells in both patient groups.
- PD-1/PD-L1 blockade partially or fully reversed HCV F-induced T cell inhibition and apoptosis.
- Blocking PD-L1 elevated Th1 and Th2 cytokine levels.
Conclusions:
- The PD-1/PD-L1 pathway is involved in HCV F protein-mediated immunoregulation.
- PD-1/PD-L1 blockade is a promising strategy for restoring T cell function in chronic HCV.
- This blockade may help overcome immune impairment in chronic HCV patients.
Related Concept Videos
01:25Hepatitis
01:30Inhibitors of Viral Protein Synthesis